Targeting the p53 signaling pathway in cancer therapy the promises, challenges and perils

Expert Opinion on Therapeutic Targets

Volumn 16, Issue 1, 2012, Pages 67-83

  Stegh, Alexander H ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Cell cycle; Cell death; Mdm2 inhibitors; P53; P53 gene therapy; Senescence; Transactivation

Indexed keywords

4 (3 DIMETHYLAMINOPROPYLAMINO) 2 (4 METHOXYSTYRYL)QUINAZOLINE; ALT 801; ANTINEOPLASTIC AGENT; CISPLATIN; CONTUSUGENE LADENOVEC; ELLIPTICINE; FLUOROURACIL; GENDICINE; IGN 225; INGN 225; LONTUCIREV; MI 219; MI 319; MIRA 3; NSC 66811; NUTLIN 1; P53 REACTIVATION AND INDUCTION OF MASSIVE APOPTOSIS 1 MET; PHIKAN 082; PNX 727; PNX 822; PROTEIN BCL 2; PROTEIN P53; PXN 727; REACTIVATION OF P53 AND INDUCTION OF TUMOR CELL APOPTOSIS MOLECULE; REACTIVATION OF TRANSCRIPTIONAL REPORTER ACTIVITY MOLECULE; SCH 529074; SCH 58500; SERDEMETAN; SH GROUP TARGETING AND INDUCTION OF MASSIVE APOPTOSIS MOLECULE; SJ 172550; SULFONAMIDE; TDP 521252; TDP 665759; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AGING; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER GROWTH; CANCER INHIBITION; CANCER STEM CELL; CELL AGING; CELL CYCLE PROGRESSION; CELL DEATH; DNA REPAIR; DRUG POTENTIATION; EXPERIMENTAL MODEL; GENE ACTIVATION; GENE MUTATION; GENE THERAPY; GENETIC TRANSCRIPTION; GENOMICS; GLIOMA; HUMAN; MITOCHONDRION; NONHUMAN; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTINEOPLASTIC AGENTS; GENE THERAPY; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84855903282     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2011.643299     Document Type: Review

References (190)

1. Vousden KH, Lane DP. p53 in health and disease. Nat Rev Mol Cell Biol 2007;8:275-83 (Pubitemid 46474662)
2. Lane DP, Crawford LV. T antigen is bound to a host protein in SV40-transformed cells. Nature 1979;278:261-3 (Pubitemid 9129076)
3. Sarnow P, Ho YS, Williams J, Levine AJ. Adenovirus E1b-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kd cellular protein in transformed cells. Cell 1982;28:387-94 (Pubitemid 12132769)
4. Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 1990;248:76-9
5. Scheffner M, Werness BA, Huibregtse JM, et al. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990;63:1129-36 (Pubitemid 120035062)
6. Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol 2010;2:a001008
7. Robles AI, Harris CC. Clinical outcomes and correlates of TP53 mutations and cancer. Cold Spring Harb Perspect Biol 2010;2:a001016
8. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990;250:1233-8 (Pubitemid 120031831)
9. Donehower LA, Harvey M, Slagle BL, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992;356:215-21
10. Beckerman R, Prives C. Transcriptional regulation by p53. Cold Spring Harb Perspect Biol 2010;2:a000935
11. Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell 2009;137:413-31
12. Yonish-Rouach E, Resnitzky D, Lotem J, et al. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 1991;352:345-7 (Pubitemid 21912356)
13. Clarke AR, Purdie CA, Harrison DJ, et al. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 1993;362:849-52 (Pubitemid 23132162)
14. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993;74:957-67 (Pubitemid 23289454)
15. Lowe SW, Schmitt EM, Smith SW, et al. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993;362:847-9 (Pubitemid 23132161)
16. Liu X, Yue P, Khuri FR, Sun SY. p53 upregulates death receptor 4 expression through an intronic p53 binding site. Cancer Res 2004;64:5078-83 (Pubitemid 39006522)
17. Muller M, Wilder S, Bannasch D, et al. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med 1998;188:2033-45 (Pubitemid 28562520)
18. Sheikh MS, Burns TF, Huang Y, et al. p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha. Cancer Res 1998;58:1593-8 (Pubitemid 28215076)
19. Peter ME, Krammer PH. The CD95 (APO-1/Fas) DISC and beyond. Cell Death Differ 2003;10:26-35
20. Ehrhardt H, Hacker S, Wittmann S, et al. Cytotoxic drug-induced, p53-mediated upregulation of caspase-8 in tumor cells. Oncogene 2008;27:783-93 (Pubitemid 351186307)
21. Attardi LD, Reczek EE, Cosmas C, et al. PERP, an apoptosis-associated target of p53, is a novel member of the PMP-22/gas3 family. Genes Dev 2000;14:704-18 (Pubitemid 30176824)
22. Davies L, Gray D, Spiller D, et al. P53 apoptosis mediator PERP: localization, function and caspase activation in uveal melanoma. J Cell Mol Med 2009;13:1995-2007
23. Stegh AH, Peter ME. Apoptosis and caspases. Cardiol Clin 2001;19:13-29 (Pubitemid 32433913)
24. Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008;9:47-59
25. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995;80:293-9
26. Yu J, Zhang L, Hwang PM, et al. PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell 2001;7:673-82 (Pubitemid 32706358)
27. Nakano K, Vousden KH. PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 2001;7:683-94 (Pubitemid 32706359)
28. Oda E, Ohki R, Murasawa H, et al. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 2000;288:1053-8 (Pubitemid 30324238)
29. Han J, Flemington C, Houghton AB, et al. Expression of bbc3, a pro-apoptotic BH3-only gene, is regulated by diverse cell death and survival signals. Proc Natl Acad Sci USA 2001;98:11318-23 (Pubitemid 32928726)
30. Soengas MS, Alarcon RM, Yoshida H, et al. Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition. Science 1999;284:156-9 (Pubitemid 29282071)
31. Jeffers JR, Parganas E, Lee Y, et al. Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. Cancer Cell 2003;4:321-8 (Pubitemid 37329796)
32. Villunger A, Michalak EM, Coultas L, et al. p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science 2003;302:1036-8 (Pubitemid 37386194)
33. Chipuk JE, Maurer U, Green DR, Schuler M. Pharmacologic activation of p53 elicits Bax-dependent apoptosis in the absence of transcription. Cancer Cell 2003;4:371-81 (Pubitemid 37491098)
34. Caelles C, Helmberg A, Karin M. p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature 1994;370:220-3 (Pubitemid 24236778)
35. Johnson TM, Meade K, Pathak N, et al. Knockin mice expressing a chimeric p53 protein reveal mechanistic differences in how p53 triggers apoptosis and senescence. Proc Natl Acad Sci USA 2008;105:1215-20 (Pubitemid 351397033)
36. Chipuk JE, Bouchier-Hayes L, Kuwana T, et al. PUMA couples the nuclear and cytoplasmic proapoptotic function of p53. Science 2005;309:1732-5 (Pubitemid 41285944)
37. Chipuk JE, Kuwana T, Bouchier-Hayes L, et al. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 2004; 303:1010-14 (Pubitemid 38209704)
38. Mihara M, Erster S, Zaika A, et al. p53 has a direct apoptogenic role at the mitochondria. Mol Cell 2003;11:577-90 (Pubitemid 36385115)
39. Leu JI, Dumont P, Hafey M, et al. Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nat Cell Biol 2004;6:443-50 (Pubitemid 38607505)
40. Stegh AH, Chin L, Louis DN, DePinho RA. What drives intense apoptosis resistance and propensity for necrosis in glioblastoma? A role for Bcl2L12 as a multifunctional cell death regulator. Cell Cycle 2008;7:2833-9
41. Stegh AH, Kesari S, Mahoney JE, et al. Bcl2L12-mediated inhibition of effector caspase-3 and caspase-7 via distinct mechanisms in glioblastoma. Proc Natl Acad Sci USA 2008;105:10703-8
42. Stegh AH, Kim H, Bachoo RM, et al. Bcl2L12 inhibits post-mitochondrial apoptosis signaling in glioblastoma. Genes Dev 2007;21:98-111 (Pubitemid 46089711)
43. Stegh AH, Brennan C, Mahoney JA, et al. Glioma oncoprotein Bcl2L12 inhibits the p53 tumor suppressor. Genes Dev 2010;24:2194-204
44. Stegh AH, Depinho RA. Beyond effector caspase inhibition: Bcl2L12 neutralizes p53 signaling in glioblastoma. Cell Cycle 2011;10:33-8
45. Kumar S. Caspase 2 in apoptosis, the DNA damage response and tumour suppression: enigma no more? Nat Rev Cancer 2009;9:897-903
46. Tinel A, Tschopp J. The PIDDosome, a protein complex implicated in activation of caspase-2 in response to genotoxic stress. Science 2004;304:843-6 (Pubitemid 38620177)
47. Lin Y, Ma W, Benchimol S. Pidd, a new death-domain-containing protein, is induced by p53 and promotes apoptosis. Nat Genet 2000;26:122-7
48. Zong WX, Thompson CB. Necrotic death as a cell fate. Genes Dev 2006;20:1-15 (Pubitemid 43042662)
49. Yuan J, Kroemer G. Alternative cell death mechanisms in development and beyond. Genes Dev 2010;24: 2592-602
50. Tu HC, Ren D, Wang GX, et al. The p53-cathepsin axis cooperates with ROS to activate programmed necrotic death upon DNA damage. Proc Natl Acad Sci USA 2009;106:1093-8
51. Giono LE, Manfredi JJ. The p53 tumor suppressor participates in multiple cell cycle checkpoints. J Cell Physiol 2006;209:13-20 (Pubitemid 44318664)
52. Sherr CJ. G1 phase progression: cycling on cue. Cell 1994;79:551-5 (Pubitemid 24363798)
53. el-Deiry WS, Harper JW, O'Connor PM, et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 1994;54:1169-74 (Pubitemid 24108052)
54. el-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-25
55. Brugarolas J, Chandrasekaran C, Gordon JI, et al. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 1995;377:552-7
56. Deng C, Zhang P, Harper JW, et al. Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 1995;82:675-84
57. Waldman T, Kinzler KW, Vogelstein B. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res 1995;55:5187-90
58. Rohaly G, Chemnitz J, Dehde S, et al. A novel human p53 isoform is an essential element of the ATR-intra-S phase checkpoint. Cell 2005;122:21-32 (Pubitemid 40977937)
59. St Clair S, Giono L, Varmeh-Ziaie S, et al. DNA damage-induced downregulation of Cdc25C is mediated by p53 via two independent mechanisms: one involves direct binding to the cdc25C promoter. Mol Cell 2004;16:725-36 (Pubitemid 39586531)
60. Hermeking H, Lengauer C, Polyak K, et al. 14-3-3tau is a p53-regulated inhibitor of G2/M progression. Mol Cell 1997;1:3-11 (Pubitemid 127376388)
61. Ando T, Kawabe T, Ohara H, et al. Involvement of the interaction between 56. p21 and proliferating cell nuclear antigen for the maintenance of G2/M arrest after DNA damage. J Biol Chem 2001;276:42971-7
62. Charrier-Savournin FB, Chateau MT, Gire V, et al. p21-Mediated nuclear retention of cyclin B1-Cdk1 in response to genotoxic stress. Mol Biol Cell 2004;15:3965-76 (Pubitemid 39122002)
63. Smits VA, Klompmaker R, Vallenius T, et al. p21 inhibits Thr161 phosphorylation of Cdc2 to enforce the G2 DNA damage checkpoint. J Biol Chem 2000;275:30638-43
64. Zhan Q, Antinore MJ, Wang XW, et al. Association with Cdc2 and inhibition of Cdc2/Cyclin B1 kinase activity by the p53-regulated protein Gadd45. Oncogene 1999;18:2892-900 (Pubitemid 29250879)
65. Jin S, Antinore MJ, Lung FD, et al. The GADD45 inhibition of Cdc2 kinase correlates with GADD45-mediated growth suppression. J Biol Chem 2000;275:16602-8 (Pubitemid 30398886)
66. Nezi L, Musacchio A. Sister chromatid tension and the spindle assembly checkpoint. Curr Opin Cell Biol 2009;21:785-95
67. Cross SM, Sanchez CA, Morgan CA, et al. A p53-dependent mouse spindle checkpoint. Science 1995; 267:1353-6
68. Di Leonardo A, Khan SH, Linke SP, et al. DNA rereplication in the presence of mitotic spindle inhibitors in human and mouse fibroblasts lacking either p53 or pRb function. Cancer Res 1997;57:1013-19 (Pubitemid 27138591)
69. Fukasawa K, Choi T, Kuriyama R, et al. Abnormal centrosome amplification in the absence of p53. Science 1996;271:1744-7 (Pubitemid 26102826)
70. Lanni JS, Jacks T. Characterization of the p53-dependent postmitotic checkpoint following spindle disruption. Mol Cell Biol 1998;18: 1055-64 (Pubitemid 28063440)
71. Smith ML, Chen IT, Zhan Q, et al. Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. Science 1994;266:1376-80
72. Smith ML, Kontny HU, Zhan Q, et al. Antisense GADD45 expression results in decreased DNA repair and sensitizes cells to u.v.-irradiation or cisplatin. Oncogene 1996;13:2255-63 (Pubitemid 26411576)
73. Janus F, Albrechtsen N, Dornreiter I, et al. The dual role model for p53 in maintaining genomic integrity. Cell Mol Life Sci 1999;55:12-27 (Pubitemid 29077851)
74. Gottlieb E, Vousden KH. p53 regulation of metabolic pathways. Cold Spring Harb Perspect Biol 2010;2:a001040
75. Ma W, Sung HJ, Park JY, et al. A pivotal role for p53: balancing aerobic respiration and glycolysis. J Bioenerg Biomembr 2007;39:243-6 (Pubitemid 47619376)
76. Kulawiec M, Ayyasamy V, Singh KK. p53 regulates mtDNA copy number and mitocheckpoint pathway. J Carcinog 2009;8:8
77. Lebedeva MA, Eaton JS, Shadel GS. Loss of p53 causes mitochondrial DNA depletion and altered mitochondrial reactive oxygen species homeostasis. Biochim Biophys Acta 2009;1787:328-34
78. Matoba S, Kang JG, Patino WD, et al. p53 regulates mitochondrial respiration. Science 2006;312:1650-3 (Pubitemid 43902663)
79. Okamura S, Ng CC, Koyama K, et al. Identification of seven genes regulated by wild-type p53 in a colon cancer cell line carrying a well-controlled wild-type p53 expression system. Oncol Res 1999;11:281-5
80. Schwartzenberg-Bar-Yoseph F, Armoni M, Karnieli E. The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression. Cancer Res 2004;64:2627-33 (Pubitemid 38523921)
81. Kawauchi K, Araki K, Tobiume K, Tanaka N. p53 regulates glucose metabolism through an IKK-NF-kappaB pathway and inhibits cell transformation. Nat Cell Biol 2008;10:611-18 (Pubitemid 351627381)
82. Kondoh H, Lleonart ME, Gil J, et al. Glycolytic enzymes can modulate cellular life span. Cancer Res 2005;65:177-85 (Pubitemid 40070808)
83. Bensaad K, Vousden KH. p53: new roles in metabolism. Trends Cell Biol 2007;17:286-91 (Pubitemid 46829848)
84. Li H, Jogl G. Structural and biochemical studies of TIGAR (TP53-induced glycolysis and apoptosis regulator). J Biol Chem 2009;284:1748-54
85. Vousden KH. Functions of p53 in metabolism and invasion. Biochem Soc Trans 2009;37:511-17
86. Muniyappa H, Song S, Mathews CK, Das KC. Reactive oxygen species-independent oxidation of thioredoxin in hypoxia: inactivation of ribonucleotide reductase and redox-mediated checkpoint control. J Biol Chem 2009;284:17069-81
87. Budanov AV, Sablina AA, Feinstein E, et al. Regeneration of peroxiredoxins by p53-regulated sestrins, homologs of bacterial AhpD. Science 2004;304:596-600 (Pubitemid 38541920)
88. Cano CE, Gommeaux J, Pietri S, et al. Tumor protein 53-induced nuclear protein 1 is a major mediator of p53 antioxidant function. Cancer Res 2009;69:219-26
89. Chen W, Sun Z, Wang XJ, et al. Direct interaction between Nrf2 and p21(Cip1/WAF1) upregulates the Nrf2-mediated antioxidant response. Mol Cell 2009;34:663-73
90. Hayflick L. The limited in vitro lifetime of human diploid cell strains. Exp Cell Res 1965;37:614-36
91. Zilfou JT, Lowe SW. Tumor suppressive functions of p53. Cold Spring Harb Perspect Biol 2009;1:a001883
92. Brown JP, Wei W, Sedivy JM. Bypass of senescence after disruption of p21CIP1/WAF1 gene in normal diploid human fibroblasts. Science 1997;277:831-4 (Pubitemid 27366737)
93. Narita M, Nunez S, Heard E, et al. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 2003;113:703-16 (Pubitemid 36724935)
94. Narita M, Krizhanovsky V, Nunez S, et al. A novel role for high-mobility group a proteins in cellular senescence and heterochromatin formation. Cell 2006;126:503-14 (Pubitemid 44163608)
95. Gorgoulis VG, Zacharatos P, Kotsinas A, et al. p53 activates ICAM-1 (CD54) expression in an NF-kappaB-independent manner. EMBO J 2003;22:1567-78 (Pubitemid 36417405)
96. Xue W, Zender L, Miething C, et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007;445:656-60 (Pubitemid 46232886)
97. Campisi J. Cancer and ageing: rival demons? Nat Rev Cancer 2003;3:339-49 (Pubitemid 37328854)
98. Vijg J, Suh Y. Genetics of longevity and aging. Annu Rev Med 2005;56:193-212 (Pubitemid 40299780)
99. Blanpain C, Fuchs E. Epidermal homeostasis: a balancing act of stem cells in the skin. Nat Rev Mol Cell Biol 2009;10:207-17
100. Orkin SH, Zon LI. Hematopoiesis: an evolving paradigm for stem cell biology. Cell 2008;132: 631-44 (Pubitemid 351260057)
101. Schoppy DW, Ruzankina Y, Brown EJ. Removing all obstacles: a critical role for p53 in promoting tissue renewal. Cell Cycle 2010;9:1313-19
102. Tyner SD, Venkatachalam S, Choi J, et al. p53 mutant mice that display early ageing-associated phenotypes. Nature 2002;415:45-53 (Pubitemid 34062443)
103. Dumble M, Moore L, Chambers SM, et al. The impact of altered p53 dosage on hematopoietic stem cell dynamics during aging. Blood 2007;109:1736-42 (Pubitemid 46239609)
104. Matheu A, Maraver A, Klatt P, et al. Delayed ageing through damage protection by the Arf/p53 pathway. Nature 2007;448:375-9 (Pubitemid 47080339)
105. Garcia-Cao I, Garcia-Cao M, Tomas-Loba A, et al. Increased p53 activity does not accelerate telomere-driven ageing. EMBO Rep 2006;7:546-52 (Pubitemid 43904873)
106. Ventura A, Kirsch DG, McLaughlin ME, et al. Restoration of p53 function leads to tumour regression in vivo. Nature 2007;445:661-5 (Pubitemid 46232887)
107. Martins CP, Brown-Swigart L, Evan GI. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 2006;127:1323-34 (Pubitemid 44960417)
108. Junttila MR, Karnezis AN, Garcia D, et al. Selective activation of p53-mediated tumour suppression in high-grade tumours. Nature 2010;468:567-71
109. Feldser DM, Kostova KK, Winslow MM, et al. Stage-specific sensitivity to p53 restoration during lung cancer progression. Nature 2010;468:572-5
110. Bykov VJ, Issaeva N, Selivanova G, Wiman KG. Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database. Carcinogenesis 2002;23:2011-18. Available from: http://www.cancer.gov/ clinicaltrials/ (Pubitemid 36104953)
111. Kock H, Harris MP, Anderson SC, et al. Adenovirus-mediated p53 gene transfer suppresses growth of human glioblastoma cells in vitro and in vivo. Int J Cancer 1996;67:808-15 (Pubitemid 26348809)
112. Gomez-Manzano C, Fueyo J, Kyritsis AP, et al. Adenovirus-mediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosis. Cancer Res 1996;56:694-9 (Pubitemid 26055454)
113. Gomez-Manzano C, Fueyo J, Kyritsis AP, et al. Characterization of p53 and p21 functional interactions in glioma cells en route to apoptosis. J Natl Cancer Inst 1997;89:1036-44 (Pubitemid 27327868)
114. Lang FF, Yung WK, Sawaya R, Tofilon PJ. Adenovirus-mediated p53 gene therapy for human gliomas. Neurosurgery 1999;45:1093-104 (Pubitemid 29517513)
115. Li H, Alonso-Vanegas M, Colicos MA, et al. Intracerebral adenovirus-mediated p53 tumor suppressor gene therapy for experimental human glioma. Clin Cancer Res 1999;5:637-42 (Pubitemid 29131975)
116. Lang FF, Bruner JM, Fuller GN, et al. Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J Clin Oncol 2003;21:2508-18 (Pubitemid 46606332)
117. Nemunaitis J, Clayman G, Agarwala SS, et al. Biomarkers predict p53 gene therapy efficacy in recurrent squamous cell carcinoma of the head and neck. Clin Cancer Res 2009;15:7719-25
118. Zeimet AG, Marth C. Why did p53 gene therapy fail in ovarian cancer? Lancet Oncol 2003;4:415-22 (Pubitemid 36833683)
119. Nemunaitis J, Ganly I, Khuri F, et al. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a Phase II trial. Cancer Res 2000;60:6359-66
120. Shi J, Zheng D. An update on gene therapy in China. Curr Opin Mol Ther 2009;11:547-53
121. Yang ZX, Wang D, Wang G, et al. Clinical study of recombinant adenovirus-p53 combined with fractionated stereotactic radiotherapy for hepatocellular carcinoma. J Cancer Res Clin Oncol 2010;136:625-30
122. Tian G, Liu J, Zhou JS, Chen W. Multiple hepatic arterial injections of recombinant adenovirus p53 and 5-fluorouracil after transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a pilot phase II trial. Anticancer Drugs 2009;20:389-95
123. Senzer N, Nemunaitis J, Nemunaitis M, et al. p53 therapy in a patient with Li-Fraumeni syndrome. Mol Cancer Ther 2007;6:1478-82 (Pubitemid 46954014)
124. Xie YS, Zhang YH, Liu SP, et al. Synergistic gastric cancer inhibition by chemogenetherapy with recombinant human adenovirus p53 and epirubicin: an in vitro and in vivo study. Oncol Rep 2010;24:1613-20
125. Pan JJ, Zhang SW, Chen CB, et al. Effect of recombinant adenovirus-p53 combined with radiotherapy on long-term prognosis of advanced nasopharyngeal carcinoma. J Clin Oncol 2009;27:799-804
126. Li Y, Li LJ, Zhang ST, et al. In vitro and clinical studies of gene therapy with recombinant human adenovirus-p53 injection for oral leukoplakia. Clin Cancer Res 2009;15:6724-31
127. Keedy V, Wang W, Schiller J, et al. Phase I study of adenovirus p53 administered by bronchoalveolar lavage in patients with bronchioloalveolar cell lung carcinoma: ECOG 6597. J Clin Oncol 2008;26:4166-71
128. Ulasov IV, Tyler MA, Han Y, et al. Novel recombinant adenoviral vector that targets the interleukin-13 receptor alpha2 chain permits effective gene transfer to malignant glioma. Hum Gene Ther 2007;18:118-29 (Pubitemid 46446049)
129. Bischoff JR, Kirn DH, Williams A, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996;274:373-6 (Pubitemid 26353341)
130. Khuri FR, Nemunaitis J, Ganly I, et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000;6:879-85 (Pubitemid 30644745)
131. O'Shea CC, Johnson L, Bagus B, et al. Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell 2004;6:611-23 (Pubitemid 40017704)
132. Chiocca EA, Abbed KM, Tatter S, et al. A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Mol Ther 2004;10:958-66 (Pubitemid 39419921)
133. Crompton AM, Kirn DH. From ONYX-015 to armed vaccinia viruses: the education and evolution of oncolytic virus development. Curr Cancer Drug Targets 2007;7:133-9 (Pubitemid 46348627)
134. Tyler MA, Ulasov IV, Sonabend AM, et al. Neural stem cells target intracranial glioma to deliver an oncolytic adenovirus in vivo. Gene Ther 2009;16:262-78
135. Sonabend AM, Ulasov IV, Tyler MA, et al. Mesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial glioma. Stem Cells 2008;26:831-41
136. Lee JT, Gu W. The multiple levels of regulation by p53 ubiquitination. Cell Death Differ 2010;17:86-92
137. Wade M, Wang YV, Wahl GM. The p53 orchestra: Mdm2 and Mdmx set the tone. Trends Cell Biol 2010;20:299-309
138. Sherr CJ. Divorcing ARF and p53: an unsettled case. Nat Rev Cancer 2006;6:663-73 (Pubitemid 44285999)
139. Vassilev LT. Small-molecule antagonists of p53-MDM2 binding: research tools and potential therapeutics. Cell Cycle 2004;3:419-21 (Pubitemid 40278226)
140. Shangary S, Qin D, McEachern D, et al. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci USA 2008;105:3933-8 (Pubitemid 351723502)
141. Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004;303:844-8 (Pubitemid 38174664)
142. Shangary S, Wang S. Small-molecule inhibitors of the MDM2-p53 protein protein interaction to reactivate p53 function: a novel approach for cancer therapy. Annu Rev Pharmacol Toxicol 2009;49:223-41
143. Kojima K, Konopleva M, Samudio IJ, et al. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood 2005;106:3150-9 (Pubitemid 41565913)
144. Secchiero P, Melloni E, di Iasio MG, et al. Nutlin-3 up-regulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feedback antiapoptotic mechanism. Blood 2009;113:4300-8
145. Carter BZ, Mak DH, Schober WD, et al. Simultaneous activation of p53 and inhibition of XIAP enhance the activation of apoptosis signaling pathways in AML. Blood 2010;115:306-14
146. Alimonti A, Nardella C, Chen Z, et al. A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis. J Clin Invest 2010;120:681-93
147. Shangary S, Ding K, Qiu S, et al. Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer. Mol Cancer Ther 2008;7:1533-42
148. Galatin PS, Abraham DJ. A nonpeptidic sulfonamide inhibits the p53-mdm2 interaction and activates p53-dependent transcription in mdm2-overexpressing cells. J Med Chem 2004;47:4163-5 (Pubitemid 39045423)
149. Lu Y, Nikolovska-Coleska Z, Fang X, et al. Discovery of a nanomolar inhibitor of the human murine double minute 2 (MDM2)-p53 interaction through an integrated, virtual database screening strategy. J Med Chem 2006;49:3759-62 (Pubitemid 43967873)
150. Yin H, Lee GI, Park HS, et al. Terphenyl-based helical mimetics that disrupt the p53/HDM2 interaction. Angew Chem Int Ed Engl 2005;44:2704-7 (Pubitemid 40689569)
151. Koblish HK, Zhao S, Franks CF, et al. Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo. Mol Cancer Ther 2006;5:160-9
152. Essmann F, Schulze-Osthoff K. Translational approaches targeting the p53 pathway for anticancer therapy. Br J Pharmacol 2011;published online 30 Jun 2011; doi:10.1111/j.1476-5381.2011.01570.x
153. Hardcastle IR, Liu J, Valeur E, et al. Isoindolinone inhibitors of the murine double minute 2 (MDM2)-p53 protein-protein interaction: structure-activity studies leading to improved potency. J Med Chem 2011;54:1233-43
154. Hardcastle IR, Ahmed SU, Atkins H, et al. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction based on an isoindolinone scaffold. J Med Chem 2006;49:6209-21 (Pubitemid 44595198)
155. Blagosklonny MV, Darzynkiewicz Z. Cyclotherapy: protection of normal cells and unshielding of cancer cells. Cell Cycle 2002;1:375-82
156. Sur S, Pagliarini R, Bunz F, et al. A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proc Natl Acad Sci USA 2009;106:3964-9
157. DeLeo AB. p53-based immunotherapy of cancer. Crit Rev Immunol 1998;18:29-35 (Pubitemid 27528179)
158. Speetjens FM, Kuppen PJ, Welters MJ, et al. Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer. Clin Cancer Res 2009;15:1086-95
159. Chiappori AA, Soliman H, Janssen WE, et al. INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect. Expert Opin Biol Ther 2010;10:983-91
160. Bykov VJ, Issaeva N, Shilov A, et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 2002;8:282-8 (Pubitemid 34250107)
161. Bykov VJ, Zache N, Stridh H, et al. PRIMA-1(MET) synergizes with cisplatin to induce tumor cell apoptosis. Oncogene 2005;24:3484-91 (Pubitemid 40756249)
162. Lambert JM, Gorzov P, Veprintsev DB, et al. PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell 2009;15:376-88
163. Shen J, Vakifahmetoglu H, Stridh H, et al. PRIMA-1MET induces mitochondrial apoptosis through activation of caspase-2. Oncogene 2008;27:6571-80
164. Bykov VJ, Issaeva N, Zache N, et al. Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs. J Biol Chem 2005;280:30384-91 (Pubitemid 41216221)
165. Wiman KG. Pharmacological reactivation of mutant p53: from protein structure to the cancer patient. Oncogene 2010;29:4245-52
166. Petitjean A, Mathe E, Kato S, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 2007;28:622-9 (Pubitemid 46744292)
167. Boeckler FM, Joerger AC, Jaggi G, et al. Targeted rescue of a destabilized mutant of p53 by an in silico screened drug. Proc Natl Acad Sci USA 2008;105:10360-5
168. Lane DP. Exploiting the p53 pathway for the diagnosis and therapy of human cancer. Cold Spring Harb Symp Quant Biol 2005;70:489-97 (Pubitemid 44124906)
169. Demma M, Maxwell E, Ramos R, et al. SCH529074, a small molecule activator of mutant p53, which binds p53 DNA binding domain (DBD), restores growth-suppressive function to mutant p53 and interrupts HDM2-mediated ubiquitination of wild type p53. J Biol Chem 2010;285:10198-212
170. Kravchenko JE, Ilyinskaya GV, Komarov PG, et al. Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage
171. North S, Pluquet O, Maurici D, et al. Restoration of wild-type conformation and activity of a temperature-sensitive mutant of p53 (p53(V272M)) by the cytoprotective aminothiol WR1065 in the esophageal cancer cell line TE-1. Mol Carcinog 2002;33:181-8 (Pubitemid 34195199)
172. Weinmann L, Wischhusen J, Demma MJ, et al. A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ 2008;15:718-29 (Pubitemid 351405077)
173. Belyi VA, Ak P, Markert E, et al. The origins and evolution of the p53 family of genes. Cold Spring Harb Perspect Biol 2010;2:a001198
174. Olivares-Illana V, Fahraeus R. p53 isoforms gain functions. Oncogene 2010;29:5113-19
175. Saddler C, Ouillette P, Kujawski L, et al. Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia. Blood 2008;111:1584-93 (Pubitemid 351213449)
176. Lau LM, Nugent JK, Zhao X, Irwin MS. HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function. Oncogene 2008;27:997-1003 (Pubitemid 351225385)
177. Ambrosini G, Sambol EB, Carvajal D, et al. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1. Oncogene 2007;26:3473-81 (Pubitemid 46816754)
178. Tabe Y, Sebasigari D, Jin L, et al. MDM2 antagonist nutlin-3 displays antiproliferative and proapoptotic activity in mantle cell lymphoma. Clin Cancer Res 2009;15:933-42
179. Calabro V, Mansueto G, Santoro R, et al. Inhibition of p63 transcriptional activity by p14ARF: functional and physical link between human ARF tumor suppressor and a member of the p53 family. Mol Cell Biol 2004;24:8529-40 (Pubitemid 39245074)
180. Hu B, Gilkes DM, Farooqi B, et al. MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin. J Biol Chem 2006;281:33030-5 (Pubitemid 46036685)
181. Phan J, Li Z, Kasprzak A, et al. Structure-based design of high affinity peptides inhibiting the interaction of p53 with MDM2 and MDMX. J Biol Chem 2010;285:2174-83
182. Reed D, Shen Y, Shelat AA, et al. Identification and characterization of the first small molecule inhibitor of MDMX. J Biol Chem 2010;285:10786-96
183. Wang H, Ma X, Ren S, et al. A small-molecule inhibitor of MDMX activates p53 and induces apoptosis. Mol Cancer Ther 2011;10:69-79
184. Issaeva N, Bozko P, Enge M, et al. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med 2004;10:1321-8 (Pubitemid 40022713)
185. Chargari C, Leteur C, Angevin E, et al. Preclinical assessment of JNJ-26854165 (Serdemetan), a novel tryptamine compound with radiosensitizing activity in vitro and in tumor xenografts. Cancer Lett 2011;312: 209-18
186. Smith MA, Gorlick R, Kolb EA, et al. Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program. Pediatr Blood Cancer 2011;published online 15 SEP 2011; doi:10.1002/pbc.23319
187. Kojima K, Burks JK, Arts J, Andreeff M. The novel tryptamine derivative JNJ-26854165 induces wild-type p53- and E2F1-mediated apoptosis in acute myeloid and lymphoid leukemias. Mol Cancer Ther 2010;9:2545-57
188. Walensky LD, Kung AL, Escher I, et al. Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science 2004;305:1466-70 (Pubitemid 39167667)
189. Bernal F, Tyler AF, Korsmeyer SJ, et al. Reactivation of the p53 tumor suppressor pathway by a stapled p53 peptide. J Am Chem Soc 2007;129:2456-7 (Pubitemid 46364050)
190. Marchenko ND, Wolff S, Erster S, et al. Monoubiquitylation promotes mitochondrial p53 translocation. EMBO J 2007;26:923-34